Article

Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance Study

2025-12-29

Abstract excerpt

This study aimed to identify drugs disproportionately reported with malignant neoplasm progression, an uncommon but clinically important endpoint, using large spontaneous reporting systems. Public reports were analyzed from the FDA Adverse Event Reporting System (FAERS; 2004Q1–2024Q4) and the Japanese Adverse Drug Event Report database (JADER; 2004–2024). Cases were defined using MedDRA Preferred Terms for maligna...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1c9f7963-2dee-59fc-b6da-fd24ed7c3124
DOI: 10.64898/2025.12.25.25343014

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance StudyDOI 10.64898/2025.12.25.25343014Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity Read

Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS databaseSemantic proximity Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

The Adverse Event Atlas and Signal Consensus Index: A Multi-Source Pharmacovigilance PlatformSemantic proximity Read

Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting SystemSemantic proximity Read

Hepatic Failure Associated with Immune Checkpoint Inhibitors: A Real-world Study from the Food and Drug Administration Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read

Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA DatabaseSemantic proximity Read

Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity Read

Analysis and Mining of Baloxavir Marboxil Adverse Event Signals in Elderly Patients Based on the FAERS DatabaseSemantic proximity Read